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Abstract
Background: DNA methylation has been shown to be associated with adiposity in adulthood. However, whether similar
DNA methylation patterns are associated with childhood and adolescent body mass index (BMI) is largely unknown. More
insight into this relationship at younger ages may have implications for future prevention of obesity and its related traits.
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Methods: We examined whether DNA methylation in cord blood and whole blood in childhood and adolescence was
associated with BMI in the age range from 2 to 18 years using both cross-sectional and longitudinal models. We performed
meta-analyses of epigenome-wide association studies including up to 4133 children from 23 studies. We examined the
overlap of findings reported in previous studies in children and adults with those in our analyses and calculated enrichment.
Results: DNA methylation at three CpGs (cg05937453, cg25212453, and cg10040131), each in a different age range, was
associated with BMI at Bonferroni significance, P < 1.06 × 10−7, with a 0.96 standard deviation score (SDS) (standard error
(SE) 0.17), 0.32 SDS (SE 0.06), and 0.32 BMI SDS (SE 0.06) higher BMI per 10% increase in methylation, respectively. DNA
methylation at nine additional CpGs in the cross-sectional childhood model was associated with BMI at false discovery
rate significance. The strength of the associations of DNA methylation at the 187 CpGs previously identified to be
associated with adult BMI, increased with advancing age across childhood and adolescence in our analyses. In addition,
correlation coefficients between effect estimates for those CpGs in adults and in children and adolescents also increased.
Among the top findings for each age range, we observed increasing enrichment for the CpGs that were previously
identified in adults (birth Penrichment = 1; childhood Penrichment = 2.00 × 10
−4; adolescence Penrichment = 2.10 × 10
−7).
Conclusions: There were only minimal associations of DNA methylation with childhood and adolescent BMI. With the
advancing age of the participants across childhood and adolescence, we observed increasing overlap with altered DNA
methylation loci reported in association with adult BMI. These findings may be compatible with the hypothesis that DNA
methylation differences are mostly a consequence rather than a cause of obesity.
Keywords: Body mass index, Childhood obesity, DNA methylation, Epigenetics
Background
An accumulating body of evidence suggests that exposures
in early life are associated with childhood BMI [1]. It is hy-
pothesized that changes in DNA methylation may underlie
the associations of early-life exposures with childhood adi-
posity [2–4]. Thus far, most of the evidence regarding
DNA methylation and adiposity stems from adult studies
[5–9]. The largest epigenome-wide association study
(EWAS) in adults identified cross-sectional associations
between DNA methylation at 187 loci and BMI in over 10,
000 participants [5]. Previous studies of the associations
between epigenome-wide DNA methylation and childhood
and adolescent adiposity were small and inconclusive [10–
16]. Candidate gene studies in childhood identified associa-
tions of DNA methylation in cord and childhood blood
with measures of adiposity [17–24]. Epigenome-wide asso-
ciation studies in children and adolescents, with sample
sizes ranging from 40 to 700 individuals, identified a limited
number of cytosine-phosphate-guanine sites (CpGs) associ-
ated with BMI [11–13, 15, 25]. Although findings of some
studies suggest that differences in DNA methylation may
precede the development of adiposity, recent studies in
adults, using methods such as Mendelian randomization,
posit that alterations in DNA methylation are predomin-
antly the consequence of adiposity, rather than the cause
[4, 5, 9, 26, 27]. The direction of any causal pathway has
not been robustly appraised in children. Obtaining more
knowledge on the association between DNA methylation
and adiposity already in childhood may have implications
for future prevention of obesity and its related traits.
We performed a meta-analysis of epigenome-wide asso-
ciation studies of BMI in up to 4133 participants from 23
studies. We assessed associations of DNA methylation in
cord blood, in childhood and adolescence with BMI in
children aged 2–18 years. We also compared the effect es-
timates and examined whether there was enrichment in
our data for CpGs previously identified for their associ-
ation with adolescent and adult adiposity.
Methods
Participants
We meta-analyzed epigenome-wide association studies
of cord or whole blood methylation with childhood or
adolescent body mass index (BMI). We used data from
up to 4133 participants from 23 studies collaborating in
the Pregnancy And Childhood Epigenetics (PACE) Con-
sortium, LifeCycle Project, and NutriProgram Project
(Additional file 1: Table S1A-D and Additional file 2:
Supplementary Methods) [28, 29]: ALSPAC, BAMSE,
CHAMACOS, CHOP Study, CHS, DOMInO Trial,
GECKO Drenthe cohort, Generation R Study, GOYA
study, Healthy Start Study, HELIX, INMA, IOW F1,
IOW F2, MoBa1, MoBa2, NEST, NFBC 1986, PIAMA
study, PREDO study, Project Viva, Raine, and STOPPA
(full names in Supplementary Methods). Cohort partici-
pants were mainly of European ancestry, but there were
also cohorts with (partly) non-European ethnicities (Af-
rican, Hispanic, and Aboriginals). Most cohorts are pro-
spective birth cohorts. We excluded multiple births,
siblings (maximum one child per family), physician-
diagnosed syndromic obesity cases, and any type of ma-
ternal diabetes (including gestational diabetes). Informed
consent was obtained for all participants, and all studies
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received approval from their local ethics committees
(see Additional file 2: Supplementary Methods).
DNA methylation
DNA methylation was measured in cord blood and
whole blood samples, in children and adolescents using
the Illumina Infinium® HumanMethylation450 BeadChip
assay (Illumina, San Diego, CA, USA) [30]. Each cohort
independently conducted their preferred quality control
and normalization method, see Additional file 2: Supple-
mentary Methods for details. Untransformed normalized
beta values of individual CpG sites were used as expos-
ure variables. If multiple measurements of DNA methy-
lation and BMI were available within an age range, we
used the oldest age within that range for which BMI and
DNA methylation were available at the same time point.
Outlying methylation beta values were excluded using
the following method: values < (25th percentile − 3*inter-
quartile range (3IQR)) and values > (75th percentile +
3IQR) were removed [31]. DNA methylation is
expressed as the proportion of alleles at which the DNA
was methylated at a specific site and hence takes values
from zero to one.
Childhood BMI
Height and weight were measured in each study using
established protocols as described in detail in the Add-
itional file 2: Supplementary Methods. The primary out-
come was BMI, calculated as weight/height2 in kg/m2, on a
continuous scale measured in three age ranges: 2–5 years
(early childhood), 5–10 years (late childhood), and 14–18
years (adolescence). If multiple BMI and DNA methylation
measurements were available, we used the measurements
at the oldest age within the age range for which BMI and
DNA methylation were available at the same time point.
BMI values were then transformed into sex- and age-
adjusted standard deviation scores (SDS) using LMSGrowth
[32–34]. The International Obesity Task Force (IOTF)
standard was used to define cutoffs for BMI for under-
weight, normal weight, overweight, and obesity in children,
created with the British 1990 growth reference and infor-
mation of participants on BMI, sex, and age [35, 36]. In sec-
ondary analyses, we used a binary outcome variable with
normal-weight children as controls and overweight or
obese children as cases. Underweight children were ex-
cluded from these secondary analyses. If a study had ≤ 10
participants in one of the (case or control) groups, this
study was excluded from the secondary analyses.
Covariates
Covariates included in all models were maternal covari-
ates: maternal age, maternal educational level (cohort def-
inition), maternal smoking status during pregnancy (any
smoking versus no smoking), maternal pre-pregnancy or
early pregnancy BMI and parity (multiparous versus nul-
liparous), and gestational age at birth. For details on
cohort-specific collection methods, see Additional file 2:
Supplementary Methods. We estimated white blood cell
proportions (B cells, CD8+ T cells, CD4+ T cells, granulo-
cytes, NK cells, and monocytes) using the reference-based
Houseman method with the Reinius reference in the minfi
package in R [37–40]. A sensitivity analysis using the cord
blood-specific Bakulski reference was performed in the
Generation R and ALSPAC studies [41]. Batch effects
were adjusted for using cohort-specific methods, see Add-
itional file 2: Supplementary Methods. Additional covari-
ates added in the cross-sectional childhood analyses were
birth weight and breastfeeding. The adolescent analyses
were additionally adjusted for adolescent age, sex, own
smoking status, and puberty status. Puberty status was
categorized into early puberty (if both breast and pubic
hair Tanner stages (or comparable classification) were 1,
2, or 3 and if girls were pre-menarcheal or boys did not
have voice change yet) and late puberty (if either breast or
pubic hair Tanner stages (or comparable classification)
were 4 or 5 or if girls were post-menarcheal or boys had
had their voice change) [42–44]. Further details are pro-
vided in the study-specific Additional file 2: Supplemen-
tary Methods.
Study-specific analyses
Associations of DNA methylation with childhood or
adolescent BMI were performed in individual studies on
participants with complete data on all covariates. In
studies with more than one ethnic group, each group
was analyzed separately. We used robust linear regres-
sion models for the continuous outcome of BMI-SDS
and generalized linear regression models for the case/
control analyses of overweight and obesity versus normal
weight, according to a pre-specified analysis plan. EWAS
analyses were conducted using DNA methylation at
three time points: birth, childhood and adolescence, and
BMI data collected at three time points: early childhood
(2–5 years), late childhood (5–10 years), and adolescence
(12-18y) (Table 1). We categorized the childhood period
into early and late childhood to overcome any age-
specific effects and the potential influence of the adipos-
ity rebound on the results [45]. Depending on data avail-
ability, cohorts participated in one or more of four
analyses: (analysis A) longitudinal associations of cord
blood DNA methylation with early childhood BMI (2–
5 years; 3295 children from 13 studies), (analysis B) lon-
gitudinal associations of cord blood DNA methylation
with late childhood BMI (5–10 years; 4133 children from
12 studies), (analysis C) cross-sectional associations of
childhood blood DNA methylation with childhood BMI
(2–10 years; 3371 children from 11 studies), and (ana-
lysis D) cross-sectional associations of adolescent blood
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DNA methylation with adolescent BMI (14–18 years;
2842 adolescents from 7 studies) (Table 1). Participating
studies per analysis are shown in Additional file 1: Table
S1A-D.
Cord blood analyses were adjusted for maternal age,
educational level, smoking status, pre-pregnancy or early
pregnancy BMI, parity, gestational age, batch, and esti-
mated cell type proportions. The cross-sectional analysis
in childhood was additionally adjusted for child covari-
ates birth weight and breastfeeding; in contrast, the
cross-sectional analysis in adolescence was adjusted for
the same covariates as analysis C plus adolescent sex,
age, and smoking and puberty status.
Meta-analyses
After performing quality control on all studies, we com-
bined results in a fixed-effects inverse variance-weighted
meta-analysis using METAL [46, 47]. All follow-up ana-
lyses were conducted in R [39]. The meta-analyses were
done independently by two study groups, and the results
were compared. After exclusion of probes that were
measured in only one study, that mapped to X and Y
chromosomes and probes that co-hybridized to alternate
sequences (cross-reactive probes), we included 429,959
probes for analysis A, 429,959 probes for analysis B, 429,
957 probes for analysis C, and 428,967 probes for ana-
lysis D [48, 49]. In the result files of the main meta-
analyses, we flagged probes that map to DNA containing
a single nucleotide polymorphism (SNP), to repetitive
sequence elements, or to DNA harboring an INDEL
(Additional file 3: Table S2A-D) [48, 49]. We corrected
for multiple testing using both the Bonferroni correc-
tion, which gives a significance threshold of P < 1.16 ×
10−7 (0.05/429,959), and the less stringent false discovery
rate (FDR) threshold using the method by Benjamini
and Hochberg [50]. EWAS results were summarized as
mean (and standard error) differences in BMI-SDS per
10% increase in methylation for each CpG. We created
volcano plots to visualize magnitude and direction of ef-
fect (reduced or increased methylation) along with the
level of statistical significance. We calculated the I2 stat-
istic to explore heterogeneity across studies. The I2 esti-
mates the proportion of variation in the meta-analysis
results for each CpG site that is due to between-study
differences rather than random/sampling variation. Het-
erogeneity was defined as an I2 value of > 50 and shown
graphically in forest plots. We performed leave-one-out
analyses, in which we reran the main meta-analysis re-
peatedly with one of the 23 studies removed each time,
to explore if any study influenced individual findings.
We enhanced the annotation provided by Illumina using
the UCSC Genome Browser. All of the annotations use
the human February 2009 (GRCh37/hg19) assembly. We
updated the gene names manually in all result files using
HUGO gene nomenclature, and in case they were not
found there, we used the NCBI gene website on Novem-
ber 5, 2019 [51–53].
To explore the associations for the extreme upper
values of the BMI distribution, we performed case/con-
trol analyses (overweight and obesity versus normal
weight). Underweight children were excluded from these
analyses, leading to sample sizes of N = 491 cases and
2540 controls (analysis A), N = 707 cases and 3217 con-
trols (analysis B), N = 644 cases and 2567 controls (ana-
lysis C), and N = 507 cases and 2188 controls (analysis
D) (Additional file 4: Table S3A-D).
To examine whether any of the Bonferroni-significant
or FDR-significant CpGs in our analyses were close to
Table 1 Overview of main analyses, secondary analyses, and sensitivity analyses
Analysis Main analyses Secondary analyses: binary
model (N), cases = overweight











A Birth (cord blood) Early childhood
(2–5 years)
3295 Cases = 491
Controls = 2540
2902 2989
B Birth (cord blood) Late childhood
(5–10 years)




C Childhood (whole blood) Childhood
(2–10 years)
3371 Cases = 644
Controls = 2567
3026 3171
D Adolescence (whole blood) Adolescence
(12–18 years)
2842 Cases = 507
Controls = 2188
NA NA
Analyses A and B were adjusted for maternal age, educational level, smoking status, pre-pregnancy or early pregnancy BMI, parity, gestational age at birth, batch,
and estimated cell type proportions
Analyses C was adjusted for maternal age, educational level, smoking status, pre-pregnancy or early pregnancy BMI, parity, gestational age at birth, batch,
estimated cell type proportions, birth weight, and breastfeeding
Analyses D was adjusted for maternal age, educational level, smoking status, pre-pregnancy or early pregnancy BMI, parity, gestational age at birth, batch,
estimated cell type proportions, birth weight, breastfeeding, adolescent sex, age smoking and puberty status
Vehmeijer et al. Genome Medicine          (2020) 12:105 Page 4 of 15
BMI SNPs, we assessed if these CpGs were located
within a 4-Mb window (± 2Mb) surrounding the 15 gen-
etic loci associated with childhood body mass index [2,
54]. For the FDR-significant CpGs that were flagged be-
cause they were potentially influenced by a SNP, we
visually inspected density plots in the Generation R
Study to see whether these deviated from unimodality
(Additional file 5: Supplementary Information, Fig. S6).
To explore DNA methylation patterns in the regions
around the significant CpGs, we assessed the associa-
tions of all CpGs located within a 10-kb window (± 5 kb)
surrounding these CpGs with BMI in the relevant
models (Additional file 6: Table S4).
Sensitivity analyses
To explore whether ethnic heterogeneity may have af-
fected our results, we repeated the meta-analyses includ-
ing studies with participants of European ancestry only
(N = 2902 (excluding three studies for analysis A), N =
3657 (excluding three studies for analysis B), N = 3026
(excluding two studies for analysis C)), the largest ethnic
subgroup (Additional file 7: Table S5A-C). Ethnicity was
defined using self-reported questionnaires unless speci-
fied otherwise in the study-specific Supplementary
Methods (Additional file 2). We performed additional
analyses excluding studies with a high percentage (> 30%
(percentage calculated after exclusion of underweight
children)) of children with overweight and obesity to ex-
plore whether any associations found may be driven by
more extreme values of BMI (included N = 2989 (exclud-
ing two studies for analysis A), N = 3489 (excluding four
studies for analysis B), N = 3171 (excluding one study for
analysis C) (Additional file 8: Table S6A-C). We also
performed a third, conservative, sensitivity analysis in all
age groups, excluding cohorts of non-Europeans, studies
with a high percentage (> 30%) of children with over-
weight or obesity, and studies in which the sample was
selected on or enriched for any particular exposure or
outcome (Additional file 9: Table S7A-D).
Comparison with previous findings
We explored whether CpG sites associated with child-
hood, adolescent, or adult BMI in previous studies were
associated with BMI in our data. For previous candidate
gene studies and smaller EWASs (N < 1000), we per-
formed a look-up of the hits, using a Bonferroni-adjusted
P value cutoff per study, so for each study, the cutoff was
0.05/(N CpGs from that study) (Additional file 10: Table
S8) [7, 15, 17, 18, 20, 21, 23, 24, 55]. If the specific CpGs
from a study were not available in our dataset, we looked
up all CpGs annotated to the relevant genes [17, 24]. To
establish whether the CpG sites associated with BMI in
previously reported larger EWASs (N ≥ 1000) were over-
represented among our CpGs with the smallest P values,
we examined the absolute overlap of the top CpGs from
literature with the top CpGs in our analyses [5, 6, 9, 25,
26, 56–59]. The latter were defined using two cutoffs: a
stringent cutoff of P value < 1 × 10−5 and a more lenient
one of P value < 0.05. (Additional file 11: Table S9). We
used a hypergeometric test to calculate enrichment with
the phyper function in the R Stats package in R.
We examined the 187 CpGs identified in the largest
adult study (N = 10,261) to date in more detail in our re-
sults [5]. We tested whether the enriched CpGs signifi-
cantly overlapped between our analyses using chi-square
tests. We used Pearson’s correlation coefficients to
examine the correlations between the effect estimates of
these 187 CpGs in adults and those in our analyses [5].
Using Fisher’s exact test, we calculated whether the cor-
relation coefficients at the various ages were significantly
different from each other.
Functional analyses
We explored the potential functional interpretation of
the most significantly associated CpGs (P value < 1 ×
10−4) in all models using Gene Ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) en-
richment analyses. We used the missMethyl package,
which enabled us to correct for the number of probes
per gene on the 450K array, based on the May 5, 2020,
version of the GO and the October 23, 2019, version of
the KEGG source databases [60]. To filter out the large,
general pathways, we set the number of genes for each
gene set between 5 and 2000, respectively. We report
nominal P values < 0.05 and FDR for enrichment (Add-
itional file 12, Table S10).
Results
Participants
We included 2842 to 4133 participants from 23 independ-
ent cohorts from the Pregnancy And Childhood Epigenet-
ics (PACE) Consortium [28]. We assessed associations of
DNA methylation in cord blood with BMI in early child-
hood (2–5 years) (N = 3295, analysis A), DNA methylation
in cord blood with BMI in late childhood (5–10 years)
(N = 4133, analysis B), DNA methylation in childhood
with BMI in childhood (2–10 years) (N = 3371, analysis
C), and DNA methylation in adolescence with BMI in
adolescence (12–18 years) (N = 2842, analysis D). Details
of participants and studies used in the different analyses
are presented in Table 1, Additional file 1: Table S1A-D
and Additional file 2: Supplementary Methods.
Meta-analyses
The main, secondary, and sensitivity analyses are out-
lined in Table 1. Genomic inflation factors (lambdas) for
the main meta-analyses ranged between 0.97 and 1.27
(Additional file 5: Supplementary information, Fig. 1a-d).
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Genomic inflation factors (lambdas) of all cohort-specific
analyses are shown in Additional file 1: Table S1A-D. The
main results are shown in Table 2 and Fig. 1. We did not
identify associations at genome-wide significance of DNA
methylation in cord blood with BMI in early childhood
(analysis A, Fig. 1a, and Additional file 3: Table S2A).
DNA methylation at one CpG, cg05937453 (SFRP5), in
cord blood was significantly associated with late-
childhood BMI (analysis B, Fig. 1b, and Additional file 3:
Table S2B). For each 10% increase in DNA methylation at
cg05937453 in cord blood, late-childhood BMI increased
0.96 SD (standard error (SE) 0.17). Cord blood DNA
methylation at this CpG was nominally significantly asso-
ciated with BMI in early-childhood (P value = 0.004), but
DNA methylation in childhood and adolescence was not
associated with BMI in the cross-sectional analyses (Add-
itional file 13: Table S11).
In the cross-sectional analysis (analysis C), childhood
DNA methylation at cg25212453 (SLC43A2) was associated
with childhood BMI after Bonferroni correction. A 10% in-
crease in DNA methylation at cg25212453 was associated
with a 0.32 SD (SE 0.06) increase in childhood BMI (Fig. 1c
and Additional file 3: Table S2C). DNA methylation at this
CpG at birth and in adolescence was not associated with
BMI (Additional file 13: Table S11). DNA methylation in
childhood at nine additional CpGs in or near other genes
was associated with childhood BMI using FDR P value <
0.05 (Fig. 1c and Additional file 3: Table S2C). DNA methy-
lation in adolescence at cg10040131 (SFXN5) was associ-
ated with adolescent BMI after Bonferroni correction
(analysis D, Fig. 1d and Additional file 3: Table 2d). A 10%
increase in DNA methylation at cg10040131 was associated
with a 0.32 SD (SE 0.06) higher BMI in adolescence. DNA
methylation at this CpG in childhood was nominally
significantly associated with childhood BMI (P value =
0.0002). The association of DNA methylation at this
CpG in cord blood and BMI in childhood was not sig-
nificant (Additional file 13: Table S11).
Associations of DNA methylation with BMI did not show
a preferential direction of effect in any of the analyses (vol-
cano plots, Additional file 5: Supplementary Information,
Fig. S2A-D). We observed very little evidence of heterogen-
eity between studies among the Bonferroni-significantly
associated CpG sites, with all I2 ≤ 50 (Additional file 3:
Table 2a-d and forest plots, Additional file 5: Supplemen-
tary Information, Fig. S3A, B and L). We found evidence of
Fig. 1 Manhattan plots for the meta-analyses of DNA methylation and childhood or adolescent BMI. Manhattan plots showing the meta-analysis
results for associations of DNA methylation in cord blood with early childhood BMI (a) and late childhood BMI (b), of DNA methylation in whole
blood in childhood with childhood BMI (c), and of DNA methylation in whole blood in adolescence with adolescent BMI (d). The gray line shows
the Bonferroni-corrected significance threshold for multiple testing (P < 1.06 × 10−7). The orange line shows the FDR-corrected significance
threshold for multiple testing
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between-study heterogeneity (I2 > 50) for 3 of the 9 FDR-
significantly associated CpG sites (Additional file 3: Table 2c
and forest plots, Additional file 5: Supplementary Informa-
tion, Fig. S3C-K). The results for the twelve Bonferroni or
FDR-significantly associated CpGs were stable after omit-
ting one study at a time (leave-one-out analyses, Add-
itional file 5: Supplementary Information, Fig. S4A-L).
When BMI was dichotomized into normal and over-
weight/obesity, only one CpG in the cross-sectional
model in childhood, cg06991974 (PRDM16-DT), showed
evidence of association. In the cross-sectional model
during childhood, which included 644 children with
overweight/obesity and 2567 normal-weight children,
DNA methylation at cg06991974 was associated with an
increased risk of overweight/obesity in childhood (odds
ratio (OR) 3.10, 95% confidence interval (CI) 2.08, 4.63)
(Additional file 4: Table S3A-D).
None of the three individual Bonferroni-significant CpGs
in the three different age ranges nor the 9 FDR-significant
CpGs was within a 4-Mb window surrounding the 15 known
genetic loci associated with childhood body mass index [54].
Four of the 12 FDR significant CpGs contained a
single-nucleotide polymorphism (SNP) [48, 49]. We
found no indication of non-unimodal distribution for
any of these CpGs suggesting that methylation measure-
ments at these sites were not markedly affected by SNPs
(Additional file 5: Supplementary Information, Fig. S6).
Two of the three Bonferroni-significant CpGs (cg05937453
and cg25212453) had other nearby CpGs within a 10-kb
window (± 5 kb) measured on the 450K array (Add-
itional file 6: Table S4). Cg05937453 (model B) was sur-
rounded by 24 other CpGs, of which one was nominally
significantly associated with BMI (P value < 0.05). Both were
located in the TSS200 region of SFRP5 with effect estimates
in the same direction. Cg25212453 (model C) was sur-
rounded by 13 other CpGs, of which three were nominally
significant (P values < 0.05). All were located in the gene body
of SLC43A2 with effect estimates in the same direction. Re-
sults for Bonferroni- and FDR-significant CpGs are shown in
Additional file 6: Table S4.
Sensitivity analyses
Findings were consistent with the main results when re-
stricted to up to 3657 participants of European ethnicity
(Pearson correlation coefficients of the effect estimates
across all CpG sites were 0.86–0.97 and were 0.99 across
top CpG sites (P value < 1 × 10−4) for all models (Add-
itional file 7: Table S5A-C)). Similarly, when the studies
with a high percentage (> 30%) of children with over-
weight or obesity were excluded, the results were also
consistent with the main analyses (Pearson correlation
coefficients of the effect estimates across all CpG sites
were 0.89–0.98 and were 0.99 across top CpG sites (P
value < 1 × 10−4) for all models (Additional file 8: Table
S6A-C)). Lastly, when the studies of non-Europeans par-
ticipants, a high percentage of children with overweight
or obesity and studies in which the sample was selected
on or enriched for any particular exposure or outcome
Table 2 CpG sites at which DNA methylation was associated with child or adolescent BMI
CpG CHR Location Coef SE P value FDR P value Nearest gene
Analysis B = association of cord blood DNA methylation with late childhood BMI (5–10 years)
cg05937453 10 99531765 0.96288 0.16871 1.15 × 10−8 0.0049 SFRP5
Analysis C = cross-sectional association of whole blood DNA methylation with childhood BMI (2–10 years)
cg25212453 17 1509953 0.31925 0.05978 9.27 × 10−8 0.02075 SLC43A2
cg03500056 16 8814507 0.30577 0.05767 1.15 × 10−7 0.02075 ABAT
cg05281708 3 44690673 0.65856 0.12614 1.78 × 10−7 0.02075 ZNF35
cg15125798 5 122621645 0.49705 0.09548 1.93 × 10−7 0.02075 –
cg04456029 12 113496126 0.27587 0.05358 2.63 × 10−7 0.0226 DTX1
cg03431111 11 62621406 0.19261 0.03791 3.77 × 10−7 0.0270 SNORD30; SNORD22; SNORD29;
SNORD31; SNHG1
cg26889953 15 22915992 0.31743 0.06391 6.81 × 10−7 0.0304 CYFIP1
cg19743522 12 113495566 0.33854 0.0682 6.92 × 10−7 0.0304 DTX1
cg25877069 8 95003236 − 0.45126 0.09092 6.94 × 10−7 0.0304 –
cg13931559 20 33146515 − 0.84718 0.17082 7.07 × 10−7 0.0304 MAP1LC3A
Analysis D = cross-sectional association of whole blood DNA methylation with adolescent BMI (12–18 years)
cg10040131 2 73178866 0.32434 0.0566 1.00 × 10−8 0.0043 SFXN5
Coefficients (Coef) and standard errors (SE) are presented per 10% increase in the methylation level
Analyses B was adjusted for maternal age, educational level, smoking status, pre-pregnancy or early pregnancy BMI, parity, gestational age, batch, and estimated
cell type proportions. Analysis C was additionally adjusted for child covariates birth weight and breastfeeding, whereas analysis D was adjusted for the same
covariates as analysis C plus adolescent sex, age, smoking, and puberty status
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were all excluded, results remained strongly correlated
to those from the main models. Pearson correlation
coefficients of the effect estimates across all CpG sites
were 0.64–0.97 and 0.95–0.99 across top CpG sites (P
value < 1 × 10–4) for all models (Additional file 9:
Table S7A-D).
Comparison with previous findings
Most CpGs identified to be associated with BMI in pre-
vious candidate gene studies or smaller EWASs (N <
1000) did not replicate in our results (Additional file 10:
Table S8) [7, 15, 17, 18, 20, 21, 23, 24, 55]. When com-
paring the genome-wide significant findings from the
largest BMI EWASs (N > 1000) in adults to our most sig-
nificant findings across the four age ranges, we found an
increasing overlap with age (Table 3 and Add-
itional file 11: Table S9) [5, 6, 9, 25, 26, 56–59]. We used
two cutoffs to select the most significant findings in our
results: a P value < 1 × 10−5, to identify “suggestive” find-
ings, and a less stringent, nominal P value < 0.05. The
number of CpGs that met these criteria are provided in
Table 3. First, we examined the absolute number of
overlapping CpGs between the studies in adults and our
findings with a P value < 1 × 10−5 and calculated enrich-
ment. With advancing age across childhood and adoles-
cence, we observed increasing enrichment for the 187
CpGs previously reported to be associated with adult
BMI in the largest study to date (N = 10,261) [5]. For the
two cord blood models, there was no overlap with the
adult findings (Penrichment = 1), for the cross-sectional
model in childhood 2/187 adult hits overlapped,
(Penrichment = 0.0002), and for the cross-sectional
model in adolescence 3/187 overlapped (Penrichment =
2.10 × 10−7) (Table 3 and Additional file 11: Table
S9). Using the less stringent cutoff (P value < 0.05),
this trend was even clearer. The overlap between the
187 CpGs from the adult EWAS and the CpGs in
our data with a P value < 0.05 was 8/187 CpGs
(Penrichment = 0.77, analysis A) for the association of
cord blood DNA methylation and early childhood BMI
and 11/187 CpGs (Penrichment = 0.30, analysis B) for the as-
sociation of cord blood DNA methylation and late child-
hood BMI. For the cross-sectional model in childhood, the
overlap was 61/187 CpGs (Penrichment = 1.97 × 10
−20, ana-
lysis C), and in adolescence, the overlap was 77/187 CpGs
(Penrichment = 1.68 × 10
−44, analysis D) (Table 3 and Add-
itional file 11: Table S9). Twenty-seven CpGs were among
the enriched CpGs in both the childhood and the adoles-
cent model. This overlap was not significant (P = 0.88).
Correlation coefficients between the effect estimates of
the 187 hits and the effect estimates for those CpGs in
the four models increased with age (analysis A = − 0.186
(P = 0.01), analysis B = − 0.013 (P = 0.86), analysis C =
0.604 (P = 5.31 × 10−20), and analysis D = 0.816 (P =
7.89 × 10−46). The difference in correlation coefficients
was significant for all comparisons (P’s for comparison
between correlation coefficients < 0.01) except for the
comparison between models A and B (P = 0.09).
Effect sizes of the associations for these 187 adult BMI
CpGs in our analyses increased with advancing age of chil-
dren in our analyses (Additional file 5: Supplementary In-
formation, Fig. S5). We found similar trends for
enrichment of CpGs from other EWASs in adults and ad-
olescents (Table 3) [6, 9, 25, 26, 56–59]. Of those findings
from adult studies that had a nominal P value (< 0.05) in
our models, 17–35% were reported by more than one
adult study. Most of these were found in two or three
studies, but four, cg06500161, cg19750657, cg12593793,
and cg18181703, were reported in six or seven previous
analyses.
Functional analyses
A functional enrichment analysis using genes linked to the
CpGs with P values < 1 × 10−4 in each of the models
showed no functional enrichment of Gene Ontology (GO)
terms or Kyoto Encyclopedia of Genes and Genomes
(KEGG) terms (FDR < 0.05) (Additional file 12: Table S10).
Discussion
In this large meta-analysis of EWASs of childhood and
adolescent BMI, we found little evidence of an association
between DNA methylation and childhood or adolescent
BMI. DNA methylation at three different CpGs, each one
in a different age range, was associated with BMI in early
life. With the advancing age of children in our analyses,
we observed increasing enrichment of CpGs previously
identified for their relation with adolescent or adult adi-
posity. In addition, for the 187 CpGs identified in the lar-
gest previous study of adult BMI, we found increasing
effect sizes and increasing correlations between the adult
effect sizes and those in our analyses, with age.
Interpretation of main findings
Childhood obesity is a major public health problem and
associated with short- and long-term morbidity and mor-
tality [61]. Although there is some evidence from previous
studies that DNA methylation may mediate associations
of pregnancy-related exposures with offspring adiposity,
only few specific CpG sites have been identified [4, 27].
Thus far, most of the evidence for associations of DNA
methylation with adiposity stems from adult studies.
In this study, we found little evidence of an association
between DNA methylation and childhood or adolescent
BMI. DNA methylation at three CpGs (cg05937453,
cg25212453, and cg10040131), each in a different age
range, was associated with BMI at Bonferroni signifi-
cance, P < 1.06 × 10−7. However, we did observe increas-
ing enrichment and increasing point estimates of CpGs
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Two cutoffs were used to select the significant findings in our results: a P value < 1 × 10−5, to identify “suggestive” findings, and a less stringent, nominal P value
< 0.05, to identify any trends. We used a hypergeometric test to calculate enrichment with the phyper function in the R Stats package in R. Results in bold are
nominally significant. Of those findings from adult studies that had a nominal P value (< 0.05) in our models, 17–35% were reported by more than one adult study
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previously reported in relation to adult adiposity, with
increasing age of the participants in our study [5, 6, 9,
25, 26, 57–59]. Also, correlation coefficients between ef-
fect estimates from the adult study and effect estimates
in our models increased with the age of the participants
in our study. After exclusion of invariable probes (N =
114,204) using an adult reference, the trend of increasing
enrichment of CpGs associated with adult adiposity with
advancing age remained. This result suggests that probes
reported to be invariable in adults did not strongly affect
the results of the enrichment analyses [62]. These trends
were most clearly seen in the cross-sectional analyses in
childhood and adolescence, although there was no sig-
nificant overlap in the enriched CpGs between the two
time points. This trend may partly be explained by a differ-
ence in study sample size, age range, and covariates be-
tween the models. These findings may indicate that over
time, exposure to higher “levels” of BMI may lead to differ-
ential DNA methylation. DNA methylation has been
shown to be responsive to the environment and could also
change in response to metabolic changes and the altered
adipokine/cytokine environment associated with a higher
BMI [63–65]. Methylation differences may be either in-
duced by the altered environment or result from a cellular
selection in this altered environment. If differential DNA
methylation is the result of exposure to higher BMI, it may
be part of a pathway that links adiposity to metabolic and
cardiovascular disease [5, 7]. Several studies have reported
that DNA methylation levels at obesity-associated CpG
sites were associated with cardio-metabolic factors such as
lipids, insulin resistance, and blood pressure [26, 64].
Recent studies, using methods such as Mendelian
randomization, suggested that alterations in DNA methy-
lation are predominantly a consequence of adiposity, ra-
ther than a cause [5, 7, 9, 26]. In these studies, Mendelian
randomization was used to investigate the potential causal
relationships, independent of unmeasured confounders,
between DNA methylation and BMI using genetic variants
as instrumental variables [66, 67]. Although in our study,
we cannot determine whether any of the associations are
causal, our results may be compatible with this hypothesis.
One alternative explanation for the increasing enrichment
of CpGs previously reported in relation to adult and ado-
lescent adiposity with age in our data could be that BMI at
different ages does not represent the same biological
phenotype. The DNA methylation profile may simply re-
flect the transition of childhood BMI into a different, more
adult-like BMI phenotype over time. BMI (weight(kg)/
height(m2)) is likely to have a different biological interpret-
ation at different ages, and with the increase of age, the
biological phenotype becomes more similar to adult BMI
[68]. DNA methylation at specific CpG sites is known to
change with age. We did not see any increased enrichment
of age-related CpGs identified in previous childhood and
adolescent studies with advancing age in our models (all P
values > 0.19), making it unlikely that our results represent
a strong effect of age [69, 70].
We observed only three CpGs at which DNA methyla-
tion in three different age ranges was Bonferroni-
significantly associated with BMI in childhood or adoles-
cence. Cg05937453, at which DNA methylation in cord
blood was associated with late childhood BMI, is anno-
tated to secreted frizzled-relate protein 5 (SFRP5). This
gene is part of the SFRP family that acts by modulating
Wnt signal transduction [71]. The Wnt family and SFRPs
have roles in multiple biological processes, including em-
bryonic development, inflammation, and immunity [72].
SFRP5 is an anti-inflammatory adipokine that may be in-
duced during preadipocyte proliferation, differentiation,
and maturation [65, 72]. Less is known about the other
two CpGs, cg25212453 and cg10040131, and their poten-
tial relation to adiposity. In the cross-sectional analyses in
childhood, DNA methylation at cg25212453, in the gene
body of solute carrier family 43 member 2 (SLC43A2), was
associated with BMI. SLC43A2 transcripts have been de-
scribed to be associated with fasting insulin in a whole
blood transcriptome-wide association analysis of three co-
hort studies [73]. DNA methylation at cg10040131, lo-
cated in the gene body of Sideroflexin 5 (SFXN5), was
associated with BMI in adolescence. SFXN5 has not been
described in relation to adiposity or related phenotypes.
Based on histone marks mapped by Roadmap Epige-
nomics Data Complete Collection extracted from the
UCSC Genome Browser, all 3 CpG sites coincide with a re-
gion of weak transcription in blood, and 2 CpG-sites coin-
cide with a region of weak transcription in adipose tissue,
except for cg25212453 (at SLC43A2) which coincides with
an enhancer in adipose tissue [74]. This overlap with key
regulatory elements may indicate that DNA methylation at
these CpGs could have regulatory consequences [75, 76].
Many previous studies that examined the associations
between DNA methylation and childhood BMI were not
genome-wide, were of modest sample size, or used only
FDR or less stringent cutoffs for significance [10–13, 18,
77]. Previous candidate gene studies reported that
methylation of CpGs annotated to proopiomelanocortin
(POMC), retinoid X receptor alpha (RXRA), and nitric
oxide synthase 3 (NOS3 or eNOS) was associated with
BMI in childhood [17, 24]. The exact CpGs from those
studies were either not given or were not present on the
450K Illumina array and could thus not be examined in
our data. However, none of the CpGs in our dataset that
annotated to these genes was associated with BMI in our
analyses [17, 24]. Also, methylation at CpGs in hypoxia-
inducible factor 3A (HIF3A), previously reported to be
differentially methylated in relation to BMI in adults and
children, did not show any association with BMI in
childhood or adolescence in our data [7, 20, 21, 23]. This
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finding is in concordance with two recently published
studies, both in approximately 1000 participants, which
did not find an association between childhood BMI and
methylation at HIF3A [21, 22].
Strengths and limitations
This EWAS is much larger than the previous genome-wide
studies of the association between DNA methylation and
BMI in childhood and adolescence. Other strengths of this
study are the extensive analyses from 2 to 18 years, both
longitudinal and cross-sectional. We also used a harmo-
nized analysis plan and robust methods in the PACE Con-
sortium. However, compared to studies in adults, the
sample size of this meta-analysis is still modest. All partici-
pating studies used the Infinium Human Methylation
450K array, which covers only 1.7% of all CpG sites in the
genome [78]. Thus, we cannot exclude that methylation at
other, non-measured CpGs could be associated with child-
hood BMI. The 450K BeadChip has now been replaced by
the EPIC BeadChip which includes > 850,000 CpG sites
(Illumina, San Diego, CA, USA) [78, 79]. Some previous lit-
erature included one of the participating studies in this
manuscript. We analyzed the associations between DNA
methylation and BMI at different times in childhood and
adolescence but did not study longitudinal changes in
DNA methylation in the same individuals from early life
until adulthood in relation to BMI. A recent study among
1485 adults performed cross-lagged analyses of DNA
methylation and BMI, both measured at two time points
[26]. These analyses showed significant unidirectional
paths from BMI to DNA methylation, in line with other,
cross-sectional adult studies [5, 7]. We used blood to meas-
ure DNA methylation patterns in relation to BMI, which
may not be the most relevant tissue. As overweight and
obesity are associated with an inflammatory phenotype in
the blood and may affect the white blood cell composition,
blood may be a relevant target tissue [80]. However, there
are many potentially relevant target tissues related to BMI,
including the brain, adipocytes, pancreas, liver, and many
others, and associations of DNA methylation with BMI
may differ between these tissues. In large population-based
studies, it is virtually impossible to collect samples from
these tissues. A study among adults examined whether the
associations of DNA methylation at a specific CpG in
blood and adipose tissue in relation to BMI were compar-
able and showed similar findings between the tissues [7].
We adjusted our childhood and adolescent analyses for
estimated cell type proportions using an adult reference
dataset, which is likely not an optimal way to adjust for
white blood cell proportions at these ages. However, to the
best of our knowledge, no childhood- or adolescent-
specific reference panels exist [37, 40]. Thus, we may have
been unable to fully account for potential differences in the
biology of blood at the different ages, which may have had
some influence on our results. Specific cord blood refer-
ence datasets only became available after completion of the
cohort-specific analyses [41, 81]. However, we observed no
substantial differences in results in two of our largest stud-
ies, Generation R (maximum N = 789) and ALSPAC (max-
imum N = 669), when comparing our main analyses using
the adult reference with the same analyses using cell
counts estimated with a cord blood-specific reference panel
[37, 41]. Correlation coefficients of the effect estimates of
the analyses using the adult and cord blood-specific refer-
ence panel across all 450K CpG sites were r = 0.98 and r =
0.89, respectively. Childhood BMI is influenced by genetic,
prenatal, and postnatal environmental factors. We adjusted
for a large number of potential confounding factors. How-
ever, residual confounding due to other, non-measured
factors might still be present. Individual studies contribut-
ing to this meta-analysis performed their own preferred
quality control and methylation normalization process. We
have previously shown that this does not have a large effect
on the associations of interest compared to the use of non-
normalized methylation data [82]. Meta-analyzing the
results of 23 studies may introduce between-study hetero-
geneity. We ran multiple sensitivity analyses, which showed
results that were comparable with the main findings. Based
on I2 values, most top CpGs did not show large between-
study heterogeneity, although three FDR-significant find-
ings did. These three CpG sites had I2 values of 50.2, 52.7,
and 61.8. Forest plots and leave-one-out plots did not show
large heterogeneity or an extreme effect of one study (for-
est plots (Additional file 5: Supplementary Information,
Fig.S3H, I and K and Fig. S3H, I and K). The current ana-
lyses cannot determine whether any of the associations are
causal. Future research using methods such as Mendelian
randomization could shed further light on causality,
already used by some studies in adults [5, 9, 21, 83]. Ana-
lyzing associations of BMI with DNA methylation assessed
with the EPIC BeadChip could provide new insights, as it
interrogates almost twice the number of CpG sites com-
pared to the 450K BeadChip, and particularly focuses on
CpG sites in potential regulatory regions [78, 79]. Also, bi-
sulfite sequencing methods to measure DNA methylation
could provide more detailed information. In the current
study, we analyzed differential methylation at single CpGs.
Future studies could analyze regional patterns of differen-
tial methylation (differentially methylated regions (DMRs))
and their associations with BMI to provide further bio-
logical insights. We studied BMI mostly in general popula-
tion samples. If exposure to overweight already changes
the DNA methylation profile in childhood or adolescence,
it would be interesting to analyze the associations in a
population with a more extreme phenotype of obesity in
childhood or adolescence. To examine the effects of poten-
tial interventions, studies of DNA methylation before and
after weight loss in children or adolescents could be useful.
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In adults, weight loss has been shown to be associated with
significantly different DNA methylation patterns [84–86].
Analyzing longitudinal trajectories of DNA methylation
and BMI at various time points in the same population
from birth to adolescence would help to understand fur-
ther the biological relevance of DNA methylation level
changes and patterns of change [26, 87].
Conclusions
In this large epigenome-wide association study meta-
analysis among children and adolescents, we observed
little evidence for associations between DNA methyla-
tion at individual CpGs and childhood or adolescent
BMI. With advancing age across childhood and adoles-
cence, we observed increasing effect estimates, increas-
ing correlations between adult effect sizes and those in
our analyses, and increasing enrichment of CpGs previ-
ously identified for their associations with adult adipos-
ity. These findings may be compatible with the
hypothesis that DNA methylation differences are mostly
a consequence rather than a cause of obesity, but this re-
mains to be confirmed.
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